Nature Medicine, Published online: 14 April 2026; doi:10.1038/s41591-026-04327-4 In this phase 2 trial, combination treatment with elraglusib, a cell-permeable ATP-competitive inhibitor of glycogen synthase kinase-3β, and gemcitabine plus nab-paclitaxel (GnP), in patients with previously untreated metastatic pancreatic ductal adenocarcinoma led to prolonged overall survival compared with GnP only.
Nature Medicine published a clinical update in Research Highlights on 14 Apr 2026. The item focuses on Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Open the detail page to review the full original feed content.